奈达铂联合多西他赛二线治疗晚期非小细胞肺癌的临床疗效观察  

Clinical Observation of Second Line Treatment of Nedaplatin Combined with Docetaxel on Advanced Non-small Cell Lung Cancer

作　　者：刘睿[1] 宋文广[1] 张志[1] 曹晓艳[1] 杨照环[1] 

机构地区：[1]河北医科大学唐山工人医院放化疗科,河北省唐山市063000

出　　处：《中国全科医学》2013年第6期670-672,共3页Chinese General Practice

摘　　要：目的观察奈达铂联合多西他赛治疗吉西他滨、顺铂方案耐药的晚期非小细胞肺癌(NSCLC)患者的疗效及毒副作用。方法选取2009年11月—2011年11月河北医科大学附属唐山临床医学院住院的NSCLC患者38例,给予注射用奈达铂80 mg/m2,加入0.9%氯化钠溶液500 ml中静脉滴注,第1天;多西他赛75 mg/m2,加入0.9%氯化钠溶液250 ml中静脉滴注,第1天。21 d为1个周期,每例完成2个周期后评价疗效,记录分析化疗过程中的毒副作用。近期疗效评价采用世界卫生组织(WHO)实体瘤的疗效评价标准分为:完全缓解(CR)、部分缓解(PR)、病情稳定(SD)和进展(PD)。以CR+PR计算有效率(RR);以CR+PR+SD计算疾病控制率(DCR)。结果 38例患者接受118个疗程,其中坚持2个疗程者16例,3个疗程者10例,4个疗程者6例,5个疗程者4例,6个疗程者2例,中位疗程数为3。治疗后,CR 0例,PR 13例,SD 12例,PD 13例,RR 34.2%,DCR 65.8%。均进行毒副作用评价,主要为乏力、脱发、粒细胞减少。结论奈达铂联合多西他赛治疗吉西他滨、顺铂方案耐药的晚期NSCLC患者有较好疗效,毒副作用轻微,值得临床推广应用。Objective To observe the effect and adverse reaction of Nedaplatin combined with Docetaxel in the treat- ment of advanced non - small cell lung cancer （NSCLC） patients who had resistance to Gemcitabine and Cisplatin. Methods 38 NSCLC patients admitted to Tangshan Clinical Medical College affiliated to Hebei Medical University from November 2009 to November 2011 were selected. The patients were given intravenous drip of 80 mg/m2 Nedaplatin and 75 mg/m2 Docetaxel in 500 ml and 250 ml 0. 9% sodium chloride solution for one day with 21 days as one cycle. The efficacy of each case was assessed after every two cycles, and the adverse effect was also recorded. The solid tumor assessment criterion by the WHO was used to assess the efficacy, which was categorized as CR, PR, SD and PD. The RR was calculated by CR ＋ PR while the DCR was calculated by CR ＋ PR ＋ SD. Results The 38 patients totally received 118 treatment courses, with 16 cases having 2 courses, 10 cases having 3 courses, 6 cases having 4 courses, 4 cases having 5 courses and 2 cases having 6 courses, and the median number of courses was 3. After treatment, the number of CR, PR, SD and PD was 0, 13, 12 and 13 respectively, and the RR and DCR were 34. 2% and 65.8% respectively. The adverse effects were weak, losing hair, granulocytopenia. Conclusion Nedaplatin combined with Docetaxel as second - line treatment for advanced NSCLC patients has satisfactory effect and mild adverse reac- tions. It is worthy of clinical application.

关 键 词：奈达铂 多西他赛 癌 非小细胞肺 

分 类 号：R734.2[医药卫生—肿瘤]